

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Sequelae associated with reinfection, cardiac function and long COVID, VTE in ischaemic stroke patients with and without COVID-19

#### Peer reviewed journals featured:

- A randomised clinical trial of a booster dose of CoronaVac in children and adolescents [here](#)
- Observational studies on:
  - Acute and post-acute sequelae associated with SARS-CoV-2 reinfection [here](#)
  - Cardiac function in patients with post-COVID syndrome [here](#)
  - Venous thromboembolism among acute ischaemic stroke patients with and without a history of COVID-19 [here](#)
  - Post discharge glucocorticoids and multisystem inflammatory syndrome in children [here](#)
  - Post-COVID-19 symptoms 2 years after SARS-CoV-2 infection [here](#)
  - Safety of Comirnaty (Pfizer) or CoronaVac vaccines in patients with heart failure [here](#)
  - Protection from natural SARS-CoV-2 infection compared with mRNA vaccination [here](#)
  - COVID-19-associated hospitalisations among US infants aged under 6 months [here](#)
  - Body fat percentage association with serum antibody responses to mRNA vaccines [here](#)
  - Variant-specific symptoms of COVID-19 among 1.5m adults in England [here](#)
  - Third primary mRNA vaccines in patients with haematological malignancies [here](#)
  - Early adoption of anti-SARS-CoV-2 pharmacotherapies in US veterans [here](#)
  - Immune response to the 3rd COVID-19 vaccine in immunocompromised children [here](#)
  - Monoclonal antibodies for SARS-CoV-2 infection treatment during pregnancy [here](#)
- An editorial on hybrid immunity [here](#)
- Commentary on:
  - COVID-19 and diabetes [here](#)
  - Living with COVID-19 and preparing for the future [here](#)
  - Pharmacological trials for long COVID [here](#)
  - COVID-19 vaccine effectiveness against hospitalisation with Omicron BA.4/BA.5 [here](#)
  - AstraZeneca's COVID-19 (mis)adventure and the future of vaccine equity [here](#)
  - Similarities between COVID-19 and influenza [here](#)
  - Case reports of post-vaccination adult-onset Still disease [here](#) and multisystem inflammatory syndrome leading to myocardial infarction [here](#)

## Letters and correspondence discussed:

- Neutralisation escape by Omicron subvariant BA.4.6 [here](#)
- In vitro efficacy of antiviral agents against Omicron subvariant BA.4.6 [here](#)
- Contraindications to nirmatrelvir-ritonavir (Paxlovid) in hospitalised COVID-19 patients [here](#)
- WHO living guidelines on antivirals for COVID-19 and the evidence-base [here](#)
- Association of COVID-19 vaccination with influenza vaccination [here](#)

## Pre-peer review articles featured:

- Heterogeneity and risk-of-biases of baricitinib in reducing COVID-19-related mortality [here](#)
- Liver injury in hospitalised COVID-19 patients [here](#)
- The effect of selective serotonin reuptake inhibitors in preventing long COVID [here](#)
- Selection of long COVID symptoms influences prevalence estimates in a prospective cohort [here](#)
- Acute and post-acute COVID-19 outcomes in immunologically naïve adults in the US [here](#)
- Protection against Omicron BA.5 in people with previous SARS-CoV-2 infection in Sweden [here](#)
- Conceptualising the episodic nature of disability among adults living with long COVID [here](#)
- Risk of SARS-CoV-2 reinfection in the widely vaccinated French population [here](#)
- Protection conferred by Delta and BA.1/BA.2 infection against BA.4/BA.5 [here](#)
- Risk factors and symptom clusters for long COVID in the UK [here](#)
- Data on the Omicron BQ.1 variant reveal its low potential for epidemiological expansion [here](#)
- Severity and symptom characteristics between Omicron and Delta infections in ACT [here](#)
- Chronic anti-coagulation therapy reduced mortality in patients with high cardiovascular risk [here](#)
- Neurologic sequelae of COVID-19 and immunologic imprinting from previous Coronaviruses [here](#)

## Guidance and reports

- The World Health Organization published its weekly COVID-19 epidemiological report [here](#)
- The National Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- Australian Technical Advisory Group on Immunisation (ATAGI) recommendation on use of the Pfizer COVID-19 vaccine for children aged 6 months to 4 years [here](#)
- The Therapeutic Goods Administration (TGA) provisional determination for Pfizer's COVID-19 bivalent (Comirnaty bivalent Omicron BA.4/BA.5) booster dose vaccine [here](#)

## News and blogs

- Nearly 20% of US patients receive psychiatric diagnosis within three months of COVID-19 [here](#)
- National Institute for Health and Care Excellence (NICE) rejects five COVID-19 treatments over uncertain evidence and price in draft guidance [here](#)
- China eases rules amid rise in cases [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.



Health

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.